Fig. 2: Outcome of immunomodulator maintenance and CHIP in the context of therapy related myeloid neoplasms (TMN). | Nature Communications

Fig. 2: Outcome of immunomodulator maintenance and CHIP in the context of therapy related myeloid neoplasms (TMN).

From: Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

Fig. 2

a Cumulative incidence of MDS/AML in patients with IMiD maintenance versus patients without maintenance, with death as an absorbing competing risk. Cumulative incidence of developing MDS/AML among patients with CHIP vs. no CHIP, with death as an absorbing competing risk, b among all patients, c patients receiving first-line IMiD maintenance and d patients receiving IMiDs at any point post ASCT. Groups were tested for equality using a two-sided Gray’s test to compare subdistributions for each competing risk.

Back to article page